QuiaPEG Pharmaceuticals Holding AB Cash Flow Conversion Efficiency
QuiaPEG Pharmaceuticals Holding AB cash flow conversion efficiency. Based on the latest financial reports, QuiaPEG Pharmaceuticals Holding AB (QUIA) has a cash flow conversion efficiency ratio of -0.115x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-747.00K ≈ $-80.39K USD) by net assets (Skr6.47 Million ≈ $696.28K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of QuiaPEG Pharmaceuticals Holding AB (2008–2024)
Cash flow conversion efficiency of QuiaPEG Pharmaceuticals Holding AB from 2008 to 2024. This chart illustrates how QuiaPEG Pharmaceuticals Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View QUIA live share price for real-time trading data and today's change.
QuiaPEG Pharmaceuticals Holding AB Cash Flow Conversion Ratio Explained
QuiaPEG Pharmaceuticals Holding AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
QuiaPEG Pharmaceuticals Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of QuiaPEG Pharmaceuticals Holding AB ranked by their cash flow conversion efficiency. Also see QuiaPEG Pharmaceuticals Holding AB stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RTC Group plc
LSE:RTC
|
0.106x |
|
Orcadian Energy PLC
LSE:ORCA
|
-0.093x |
|
First Class Metals PLC
LSE:FCM
|
-0.361x |
|
Essensys PLC
LSE:ESYS
|
0.045x |
|
SCANDION ONC. DK-0735
F:8VY
|
N/A |
|
Croma Security Solutions Group Plc
LSE:CSSG
|
0.003x |
|
DSW Capital PLC
LSE:DSW
|
0.184x |
|
Akoustis Technologies, Inc.
NASDAQ:AKTSQ
|
0.187x |
Annual Cash Flow Conversion Efficiency for QuiaPEG Pharmaceuticals Holding AB (2008–2024)
The table below shows the annual cash flow conversion efficiency of QuiaPEG Pharmaceuticals Holding AB from 2008 to 2024. Review QUIA free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr16.35 Million ≈ $1.76 Million |
Skr-10.17 Million ≈ $-1.09 Million |
-0.622x | +7.61% |
| 2023-12-31 | Skr15.25 Million ≈ $1.64 Million |
Skr-10.27 Million ≈ $-1.10 Million |
-0.673x | +91.07% |
| 2022-12-31 | Skr2.41 Million ≈ $259.57K |
Skr-18.18 Million ≈ $-1.96 Million |
-7.536x | +99.18% |
| 2021-12-31 | Skr22.00K ≈ $2.37K |
Skr-20.11 Million ≈ $-2.16 Million |
-914.091x | -129.27% |
| 2020-12-31 | Skr71.00K ≈ $7.64K |
Skr-28.31 Million ≈ $-3.05 Million |
-398.704x | -22715.75% |
| 2019-12-31 | Skr-8.57 Million ≈ $-922.48K |
Skr-15.11 Million ≈ $-1.63 Million |
1.763x | +109.25% |
| 2018-12-31 | Skr545.00K ≈ $58.65K |
Skr-10.39 Million ≈ $-1.12 Million |
-19.068x | -1007.89% |
| 2017-12-31 | Skr6.04 Million ≈ $649.79K |
Skr-10.39 Million ≈ $-1.12 Million |
-1.721x | -1865.23% |
| 2016-12-31 | Skr18.44 Million ≈ $1.98 Million |
Skr1.80 Million ≈ $193.49K |
0.098x | +38.56% |
| 2015-12-31 | Skr6.92 Million ≈ $744.81K |
Skr487.00K ≈ $52.41K |
0.070x | -69.52% |
| 2014-12-31 | Skr6.44 Million ≈ $693.26K |
Skr1.49 Million ≈ $160.02K |
0.231x | -24.20% |
| 2013-12-31 | Skr7.24 Million ≈ $779.57K |
Skr2.21 Million ≈ $237.40K |
0.305x | +156.89% |
| 2012-12-31 | Skr9.73 Million ≈ $1.05 Million |
Skr-5.21 Million ≈ $-560.57K |
-0.535x | -393.31% |
| 2011-12-31 | Skr13.98 Million ≈ $1.50 Million |
Skr2.55 Million ≈ $274.53K |
0.183x | +18.41% |
| 2010-12-31 | Skr17.17 Million ≈ $1.85 Million |
Skr2.65 Million ≈ $284.75K |
0.154x | +50.57% |
| 2009-12-31 | Skr17.82 Million ≈ $1.92 Million |
Skr1.82 Million ≈ $196.29K |
0.102x | +92.50% |
| 2008-12-31 | Skr17.98 Million ≈ $1.93 Million |
Skr956.00K ≈ $102.88K |
0.053x | -- |
About QuiaPEG Pharmaceuticals Holding AB
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as… Read more